Enliven (ELVN) news
Recent news
Enlivens Therapeutics, Inc.: H.C. Wainwright raises target price to $64 from $56
Enliven Therapeutics, Inc. (NASDAQ:ELVN) has seen recent upward revisions to its price targets from key analysts, reflecting growing confidence in its pipeline and market potential. On March 26, H.C. Wainwright raised its price target for the stock from $48 to $56, maintaining its Buy rating. This…
AInvest Wire · Jul 9, 2026Enlivens Therapeutics closes upsized stock offering
Enliven Therapeutics (Nasdaq: ELVN) has completed its upsized public offering, raising approximately $400.0 million in gross proceeds before underwriting discounts and other expenses. The offering included the sale of 8,933,334 shares of common stock at $37.50 per share and pre-funded warrants to…
AInvest Wire · Jun 15, 2026Enliven prices upsized share offering at $37.50/shr
Enliven Therapeutics, Inc. (Nasdaq: ELVN) has priced its public offering of 8,394,737 shares of common stock at $19.66 per share, with option for pre-funded warrants . The offering, which includes pre-funded warrants to purchase up to 1,780,263 shares at $19.659 per warrant, is expected to generate…
AInvest Wire · Jun 12, 2026Enliven: prices 8.9 mln shares at $37.50 per share
Enliven Therapeutics, Inc. (Nasdaq: ELVN) has announced the pricing of 8.9 million shares of its common stock at $37.50 per share as part of a public offering. The offering includes shares sold directly to investors and pre-funded warrants issued to certain investors, which are exercisable for…
AInvest Wire · Jun 12, 2026Enliven Therapeutics announces pricing of upsized public offering of common stock and pre-funded warrants
Enliven Therapeutics, Inc. (Nasdaq: ELVN) has announced the pricing of an upsized public offering of its common stock and pre-funded warrants, raising $250 million in gross proceeds before underwriting discounts and other expenses. The offering includes 8,394,737 shares of common stock at $19.66…
AInvest Wire · Jun 12, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.